# Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

> **NCT01658176** · PHASE2 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** PF-04691502
- **DRUG:** Exemestane
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT01658176
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658176, "Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01658176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*